In vivo Analgesic Activity of New N-arylphthalimides Derivatives in Mice
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: A series of phthalimides related to thalidomide have been studied for analgesic activity in the formalin test. The formalin test was performed in mice in a nociceptive pattern to evaluate analgesic activity.
METHODS: In this study, nine derivatives of phthalimides were evaluated in terms of exerting analgesic effects in mice. They exerted significant analgesic effects compared to indomethacin and negative control. These compounds were synthesized and characterized by TLC, followed by IR and H1NMR in the previous studies. Two distinct periods of high licking activity were used to analyze both acute and chronic pain. All compounds were compared with indomethacin and carbamazepine as positive control and vehicle as a negative control.
RESULTS: All of the tested compounds exhibited significant analgesic activity in both the first and second phases of the test compared to the control group (DMSO), although they did not show more activity than the reference drug (indomethacin) but were comparable to indomethacin.
CONCLUSION: This information may be useful in the development of a more potent phthalimide as an analgesic agent that acts as a sodium channel blocker and COX inhibitor.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Recent advances in inflammation & allergy drug discovery - 17(2023), 2 vom: 02., Seite 121-126 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Davood, Asghar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Analgesics |
|---|
| Anmerkungen: |
Date Completed 27.11.2023 Date Revised 27.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/2772270817666230302145537 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353677558 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353677558 | ||
| 003 | DE-627 | ||
| 005 | 20231226060546.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/2772270817666230302145537 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1178.xml |
| 035 | |a (DE-627)NLM353677558 | ||
| 035 | |a (NLM)36861796 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Davood, Asghar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In vivo Analgesic Activity of New N-arylphthalimides Derivatives in Mice |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.11.2023 | ||
| 500 | |a Date Revised 27.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: A series of phthalimides related to thalidomide have been studied for analgesic activity in the formalin test. The formalin test was performed in mice in a nociceptive pattern to evaluate analgesic activity | ||
| 520 | |a METHODS: In this study, nine derivatives of phthalimides were evaluated in terms of exerting analgesic effects in mice. They exerted significant analgesic effects compared to indomethacin and negative control. These compounds were synthesized and characterized by TLC, followed by IR and H1NMR in the previous studies. Two distinct periods of high licking activity were used to analyze both acute and chronic pain. All compounds were compared with indomethacin and carbamazepine as positive control and vehicle as a negative control | ||
| 520 | |a RESULTS: All of the tested compounds exhibited significant analgesic activity in both the first and second phases of the test compared to the control group (DMSO), although they did not show more activity than the reference drug (indomethacin) but were comparable to indomethacin | ||
| 520 | |a CONCLUSION: This information may be useful in the development of a more potent phthalimide as an analgesic agent that acts as a sodium channel blocker and COX inhibitor | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COX inhibitor | |
| 650 | 4 | |a formalin test | |
| 650 | 4 | |a mice | |
| 650 | 4 | |a pain | |
| 650 | 4 | |a phthalimides | |
| 650 | 4 | |a sodium channel blocker. | |
| 650 | 7 | |a Analgesics |2 NLM | |
| 650 | 7 | |a Indomethacin |2 NLM | |
| 650 | 7 | |a XXE1CET956 |2 NLM | |
| 650 | 7 | |a Cyclooxygenase Inhibitors |2 NLM | |
| 650 | 7 | |a Phthalimides |2 NLM | |
| 700 | 1 | |a Saadabadi, Atefeh |e verfasserin |4 aut | |
| 700 | 1 | |a Torkaman, Porya |e verfasserin |4 aut | |
| 700 | 1 | |a Salehi, Ehsan |e verfasserin |4 aut | |
| 700 | 1 | |a Shafaroodi, Hamed |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Recent advances in inflammation & allergy drug discovery |d 2022 |g 17(2023), 2 vom: 02., Seite 121-126 |w (DE-627)NLM322635829 |x 2772-2716 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2023 |g number:2 |g day:02 |g pages:121-126 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/2772270817666230302145537 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2023 |e 2 |b 02 |h 121-126 | ||